Ainos (NASDAQ:AIMD) versus Esperion Therapeutics (NASDAQ:ESPR) Head-To-Head Contrast

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Ainos (NASDAQ:AIMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Profitability

This table compares Esperion Therapeutics and Ainos’ net margins, return on equity and return on assets.

Institutional & Insider Ownership

47.4% of Esperion Therapeutics shares are held by institutional investors. 1.0% of Esperion Therapeutics shares are held by company insiders. Comparatively, 4.6% of Ainos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Esperion Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Ainos has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Valuation & Earnings

This table compares Esperion Therapeutics and Ainos”s revenue, earnings per share (EPS) and valuation.

Ainos has lower revenue, but higher earnings than Esperion Therapeutics.

Analyst Recommendations

This is a summary of current ratings and target prices for Esperion Therapeutics and Ainos, as reported by MarketBeat.com.

Esperion Therapeutics currently has a consensus target price of $8.17, suggesting a potential upside of 397.97%. Given Esperion Therapeutics’ higher possible upside, equities analysts plainly believe Esperion Therapeutics is more favorable than Ainos.

Summary

Esperion Therapeutics beats Ainos on 7 of the 11 factors compared between the two stocks.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

About Ainos

(Get Free Report)

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.